Personalized Antiplatelet Therapy to Prevent Recurrent Cardiovascular Events in After Ischemic Stroke
A legfontosabb adatok
- Ki végzi
- Azienda Usl di Bologna
- Hol
- Bologna, Cesena és Modena (Olaszország)Mind a 3 helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 4. fázis
- Résztvevők
- 1506 fő, tervezett
- Kezdés
- 2026. dec.
- Várható befejezés
- 2030. jún.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Acetylsalicylic acid (ASA)/aspirin 100 mg daily
- Clopidogrel 75 mg daily
- Ticlopidine 250 mg twice daily
- A regiszteradat frissítve
- 2026. november 17.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 18 feltétel megnézéseKevesebb
Ki vehet részt
- Aged ≥18 years old
- Males and females
- Non-cardioembolic ischemic stroke within the previous 14 days
- Starting or continuing secondary prevention with single or dual antiplatelet therapy after the index stroke
- Written informed consent
Ki nem vehet részt
- Concurrent need for anticoagulation for any indication
- Contraindication to study drugs
- Indications to perform carotid revascularization surgery
- Participation in a clinical trial in which an investigational drug was administered within 30 days of screening or within the 5 half-lives of the study drug, whichever is longer
- Active or previous recurrent peptic ulcer and/or gastric/intestinal bleeding, or other types of bleeding such as cerebrovascular hemorrhage
- Methotrexate used at doses equal to or greater than 15 mg/week. Combination with other potentially myelotoxic drugs. Subjects with or who have had leukopenia, thrombocytopenia, or agranulocytosis
- Known hypersensitivity to aspirin, clopidogrel or ticlopidine, or to any of the excipients
- History of asthma induced by the administration of acetylsalicylates or substances with a similar activity, especially nonsteroidal anti-inflammatory drugs
- Bleeding diathesis; coagulation disorders such as hemophilia and thrombocytopenia
- Severe hepatic impairment
- Severe renal impairment
- Uncontrolled severe cardiac failure
- Pregnancy and breastfeeding; WOCBP not using acceptable contraception during the trial period (combined [estrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device [IUD], intrauterine hormone-releasing system [IUS], bilateral tubal occlusion. vasectomised partner, sexual abstinence, progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide)
Helyszínek itt: Olaszország
- Azienda Unita Sanitaria Locale Di BolognaBologna, OlaszországToborzás még nem indult
- Azienda Unita Sanitaria Locale Della RomagnaCesena, OlaszországToborzás még nem indult
- Azienda Ospedaliero - Universitaria di ModenaModena, OlaszországToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
The TAILOR study aims to determine whether personalized antiplatelet therapy can reduce the risk of recurrent major cardiovascular events in patients who have experienced (a non-cardioembolic ischemic stroke).
A teljes eredeti leírásKevesebb
Antiplatelet medications, such as aspirin and clopidogrel, are commonly prescribed to prevent stroke recurrence. However, some patients do not respond adequately to these medications and may remain at increased risk of further cardiovascular events.
The study will compare two approaches to antiplatelet therapy: standard care, in which medications are prescribed according to current clinical practice, and personalized care (tailored care), in which treatment is adjusted based on a blood test measuring how effectively the medication inhibits platelet activity.
Participants will be randomly assigned to one of these two treatment strategies and followed for 12 months.
The main hypothesis is that tailoring antiplatelet therapy according to individual platelet response will be more effective than standard care in preventing recurrent ischemic stroke, myocardial infarction, or cardiovascular death. The study will also explore potential differences in treatment response between women and men.
A vizsgálat 2 csoportja
- Usual careMár használt kezelés, összehasonlításként
Participants in this arm will continue the antiplatelet therapy (aspirin or clopidogrel) started after the index stroke, according to usual care, independently of platelet aggregation test results. Platelet function testing is performed in all participants, but results are not disclosed to treating physicians in this arm. Patients receiving short-term DAPT will continue, at the end of the 10-day run-in period, with the single antiplatelet agent indicated by usual care (aspirin or clopidogrel), regardless of platelet aggregation test results.
Kezelés: Acetylsalicylic acid (ASA)/aspirin 100 mg daily, Clopidogrel 75 mg daily és Ticlopidine 250 mg twice daily
- Tailored careA vizsgált kezelés
Based on platelet aggregation test results (Multiplate ASPI and ADP tests), antiplatelet therapy will be tailored as follows: 1. If taking aspirin and the test confirms responsiveness, aspirin is continued. 2. If taking clopidogrel and the test confirms responsiveness, clopidogrel is continued. 3. If taking aspirin and the test shows non-responsiveness, therapy is switched to clopidogrel or ticlopidine. 4. If taking clopidogrel and the test shows non-responsiveness, therapy is switched to aspirin or ticlopidine. Patients with an indication to short-term dual antiplatelet therapy (DAPT; minor stroke with NIHSS ≤3) will undergo a 10-day run-in period and then continue with single antiplatelet therapy: patients due to continue aspirin will switch to clopidogrel if non-responders to aspirin; patients due to continue clopidogrel will switch to ticlopidine if non-responders to clopidogrel.
Kezelés: Acetylsalicylic acid (ASA)/aspirin 100 mg daily, Clopidogrel 75 mg daily és Ticlopidine 250 mg twice daily
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- Tailored Antiplatelet Secondary Prevention in Non-cardioembolic Ischemic Stroke: a Phase IV Gender-stratified Randomized Controlled Trial (TAILOR Trial)
- A regiszteradat frissítve
- 2026. november 17.